Myovant Sciences Ltd. (NYSE:MYOV) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
On August18, 2017, Myovant Sciences Ltd. (the “Company”) held its 2017 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. At the Annual Meeting, the shareholders considered and approved two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July21, 2017. Set forth below is a brief description of each matter voted upon and the results with respect to each such matter.
Proposal No.1: Mark Altmeyer, Terrie Curran, and Keith Manchester, M.D., were elected to serve as Class I Directors to serve until the Company’s 2020 Annual General Meeting of Shareholders and until their successors are duly elected, by the following votes:
|
Name |
Votes For | VotesAgainst | Abstain | BrokerNon-Votes |
|
Mark Altmeyer |
55,047,228 | 1,209,235 | 388,539 | |
|
Terrie Curran |
56,256,333 | 388,539 | ||
|
Keith Manchester, M.D. |
54,616,885 | 1,639,578 | 388,539 | |
|
Proposal No.2: The shareholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst& Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending March31, 2018, the appointment of Ernst& Young LLP as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the Company’s fiscal year ending March31, 2018 and the authorization of the Company’s Board of Directors, through the Audit Committee, to set the remuneration for Ernst& Young LLP as the Company’s auditor for the Company’s fiscal year ending March31, 2018, by the following votes: |
||||
| VotesFor | VotesAgainst | Abstain | BrokerNon-Votes | |
| 56,644,965 |
About Myovant Sciences Ltd. (NYSE:MYOV)
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
